The company valued at £1.3 billion is fleeing the shores of Britain’s increasingly high tax regime, joining the FTSE 100’s Shire Pharma in what is becoming a trend as Britain becomes less competitive.
UBM will become tax resident in Ireland, where we enjoy corporation tax rates of 12.5% compared with the 28% suffered in the UK.
Plenty of room for the rest of the FTSE 100…
